Psoriatic arthritis impacts skin and joints. It causes pain, swelling, and stiffness. This condition often follows psoriasis.

U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in ...

At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...

Much of the evidence documenting the earliest use of psilocybin in mushrooms for medicinal purposes by the ancient Mayans and Aztecs was destroyed by Spanish missionaries in the 1500s. However, that ...

With the bull market starting its fourth year, and yields on U.S. debt falling to the lowest levels since early this year, ...

Digital violence refers to any behavior that uses technology to threaten, control, humiliate, or hurt someone.

The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics ...

Yuflyma is a TNF blocker approved as a citrate-free, high-concentration, interchangeable biosimilar to Humira (adalimumab).

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

Adults with worse cardiovascular-kidney-metabolic health are at an increased risk of developing psoriasis, especially in those with high genetic risk.